

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBLT-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A68; B44, B62; Cw10, Cw5; DR4, -, DQ7, -

Summary of Results					Summary of Results				
Total tested	46	46	46	47	33	33	33	33	
Positive	1	0	0	2	0	0	0	1	
Negative	45	46	46	45	33	33	33	32	
Not Tested / Equivocal	5	5	5	4	2	2	2	2	
% Positive	2.2%	0.0%	0.0%	4.3%	0.0%	0.0%	0.0%	3.0%	
% Negative	97.8%	100.0%	100.0%	95.7%	100.0%	100.0%	100.0%	97.0%	
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	A9, DR15	DR52	DQ1	Cw2					
Lab No.	Serum 1	Without DTT		Serum 4	Serum 1	With DTT (Not assessed)		Serum 4	Comments
		Serum 2	Serum 3			Serum 2	Serum 3		
112	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
117	Equivocal	Negative	Equivocal	Negative					
119	Negative	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Negative					
128	Negative	Negative	Negative	Negative					
136	Negative	Negative	Negative	Negative					
139	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
143	NT	NT	NT	NT					
145	Negative	Negative	Negative	Negative					Poor viability
147	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	Negative	Negative	Negative	Negative					
154	Negative	Negative	Negative	Negative					
159	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
162	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
164	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
174	NT	NT	NT	NT					
181	Negative	Negative	Negative	Negative					
186	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
189	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
190	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
193	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
197	NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability
202	NT	NT	NT	NT	NT	NT	NT	NT	Insufficient viable cells
204	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
216	Negative	Negative	Negative	Negative					
223	Negative	Negative	Negative	Negative					
227	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
229	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
232	Negative	Negative	Negative	Negative					
235	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Low cell viability
238	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
243	Negative	Negative	Negative	Negative					
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
259	Positive	Negative	Negative	Positive					
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Negative	Negative	Negative	Negative					
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 16TH SEPTEMBER 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
112	-1	-1	-1	-1	-1	-1	-1	-1	18-Jul	18-Jul	Yes		No	95	Cedarlane	60	120	Stain fix
114	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	Yes		One Lambda	30	60	EB/AO
116	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	No	98	Cedarlane	20	60	EB/AO
117		1	2	1					17-Jul	17-Jul	Yes		No	80	Pel-Freeze	60	120	Fluoroquen
119	1	2	1	1	1	1	1	1	16-Jul	16-Jul	Yes		No	95	Biorad	30	60	Eosin
120	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	Yes	100	Servbio	30	60	EB/AO
126									17-Jul	17-Jul		Yes	Yes	100	Cedarlane	30	40	EB/AO
128	1	1	1	1					16-Jul	18-Jul	Yes		No	97	One Lambda	45	90	
136	1	1	1	1					16-Jul	16-Jul		Yes	Yes		In-house	60	60	EB/AO
139	1	1	1	1	1	1	1	1	17-Jul	18-Jul	Yes	Yes	Yes	90	Cedarlane	30	60	Eosin
143	NT	NT	NT	NT	NT	NT	NT	NT	17-Jul	18-Jul		Yes	Yes	70				
145									16-Jul	17-Jul		Yes	Yes	100	Invitrogen	45	45	EB/AO
147	1	1	1	1	1	1	1	1	16-Jul	16-Jul		Yes	Yes	100	In-house	30	60	Fluoroquen
149									16-Jul	18-Jul	Yes			90		60	60	Eosin
154	1	1	1	1					16-Jul	17-Jul		Yes	No	90	Cedarlane	30	60	Eosin
159	1	1	1	1	1	1	1	1	16-Jul	16-Jul		Yes	Yes	99	In-house	30	60	Fluoroquen
162									16-Jul	16-Jul		Yes	Yes	100	Cedarlane	60	60	Fluoroquen
164									16-Jul	17-Jul		Yes	Yes	90	Servbio	45	90	Fluoroquen
169	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	Yes	98	In-house	35	75	Fluoroquen
174	NT	NT	NT	NT	NT	NT	NT	NT	18-Jul	19-Jul	Yes		No	60	One Lambda	60	120	Eosin
181	1	1	1	1					16-Jul	17-Jul	Yes		No	94	Cedarlane	30	45	EB/AO
186	0	0	0	0	0	0	0	0	16-Jul	17-Jul		Yes	Yes	99	Invitrogen	30	60	Fluoroquen
189	1	1	1	1	1	1	1	1	17-Jul	18-Jul	Yes		No	88	Biorad	40	40	EB/AO
190	2	2	2	2	5	5	5	5	16-Jul	16-Jul		Yes	Yes		Cedarlane	30	60	Fluoroquen
193	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	No	99	Cedarlane	30	60	
194	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	Yes	90	In-house	30	45	Fluoroquen
195	4	4	4	4					18-Jul	18-Jul	Yes		No	60	Invitrogen	30	60	
197	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	1	1	1	1	1	1	1	17-Jul	17-Jul		Yes	No	90	Cedarlane	45	90	Fluoroquen
206	1	1	1	1	1	1	1	1	17-Jul	17-Jul		Yes	Yes	100	Cedarlane	30	45	Fluoroquen
209									16-Jul	16-Jul	Yes		No	90	Ingen	30	60	Fluoroquen
210	0	0	0	0	0	0	0	0	17-Jul	17-Jul		Yes	Yes	100	Biorad	30	60	
216	1	2	1	2					17-Jul	18-Jul	Yes		No	95	Biorad	30	60	PI
223	1	1	1	1					18-Jul	21-Jul		Yes	Yes	80	Biorad	45	60	EB/AO
227									16-Jul	16-Jul		Yes	Yes	98	Immucor	30	60	Fluoroquen
229									17-Jul	17-Jul	Yes		No		Cedarlane	30	60	
232									17-Jul	17-Jul	Yes		No	70	Biotest	45	60	Fluoroquen
235	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes		No	85	Biorad	30	60	Eosin
238	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	Yes	95	Invitrogen	45	90	Fluoroquen
243	2	2	2	2					16-Jul	17-Jul	Yes		Yes	90	Biorad	30	60	Fluoroquen
245	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	Yes	100	BAG	30	60	EB/AO
252	1	2	1-2	1	1-2	1	1	1-2	17-Jul	17-Jul		Yes	No	50	One Lambda	30	60	
259									17-Jul	17-Jul	Yes	Yes	Yes	95	Biorad	30	60	AO/PI
260									17-Jul	17-Jul		Yes	Yes	85	Biorad	30	60	EB/AO
262									17-Jul	17-Jul	Yes	Yes	Yes	90	Invitrogen	30	60	Eosin
268	1	1	1	1	1	1	1	1	16-Jul	16-Jul		Yes	No	50	Gentrak	30	60	EB/AO
284	1	1	1	1	1	1	1	1	16-Jul	16-Jul		Yes	Yes	99	Cedarlane	40	60	EB/AO
293									17-Jul	17-Jul		Yes	Yes	80	Invitrogen	60	120	Eosin
294	0	0	0	0					16-Jul	17-Jul		Yes	Yes	100	Pel-Freeze	30	30	Fluoroquen
297	1	1	1	1	1	1	1	1	17-Jul	17-Jul		Yes	Yes	>90	Cedarlane	30	60	Fluoroquen

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A68; B44, B62; Cw10, Cw5; DR4, -; DQ7, -

Summary of Results					Summary of Results				
Total tested	33	33	32	33	26	26	26	26	26
Positive	1	10	4	1	0	6	2	2	0
Negative	32	23	28	32	26	20	24	24	26
Not Tested / Equivocal	4	4	5	4	2	2	2	2	2
% Positive	3.0%	30.3%	12.5%	3.0%	0.0%	23.1%	7.7%	7.7%	0.0%
% Negative	97.0%	69.7%	87.5%	97.0%	100.0%	76.9%	92.3%	92.3%	100.0%
Consensus	Negative	Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative
HLA Antibody (Defined By CDC)	A9, DR15	DR52	DQ1	Cw2					

Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Negative					
139	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
145	Negative	Negative	Negative	Negative					
147	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
154	NT	NT	NT	NT					Low B-cell count
159	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
162	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
164	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
169	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
181	Negative	Positive	Negative	Negative					
186	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
190	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
193	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195	Negative	Positive	Negative	Negative					
197	NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability
202	NT	NT	NT	NT	NT	NT	NT	NT	Insufficient viable cells
204	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
206	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	NT	NT	NT	NT					Low cell viability
227	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
238	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
243	Negative	Positive	NT	Negative					Serum 3 - Low cell count and viability of B-cells
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
259	Positive	Positive	Positive	Positive					
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Negative	Negative	Negative	Negative					
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes		One Lambda	30	60	EB/AO
120	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes	100	Servibio	30	60	EB/AO
126									17-Jul	17-Jul	Yes	100	Cedarlane	30	40	EB/AO
139	1	6	1	1	1	6	1	1	17-Jul	18-Jul	Yes	90	Cedarlane	30	60	Eosin
145									16-Jul	17-Jul	Yes	100	Invitrogen	45	45	EB/AO
147	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	100	In-house	30	60	
154	NT	NT	NT	NT	NT	NT	NT	NT	16-Jul	17-Jul	No	<50	Cedarlane	30	60	Eosin
159	1	4	1	1	1	4	1	1	16-Jul	16-Jul	Yes	99	In-house	30	60	Fluoroquench
162									16-Jul	16-Jul	Yes	100	Cedarlane	60	60	
164									16-Jul	17-Jul	Yes	90	Servibio	45	90	Fluoroquench
169	1	1	4	1	1	1	4	1	16-Jul	17-Jul	Yes	98	In-house	35	75	Fluoroquench
181	1	6	1	1					16-Jul	17-Jul	Yes	90	Cedarlane	30	45	EB/AO
186	0	0	0	0	0	0	0	0	16-Jul	17-Jul	Yes	99	Invitrogen	30	60	Fluoroquench
190	5	5	5	5	5	5	5	5	16-Jul	16-Jul		95	Cedarlane	30	60	Fluoroquench
193	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	95	Cedarlane	30	60	
194	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes	90	In-house	30	45	Fluoroquench
195	4	8	4	4					18-Jul	18-Jul	Yes	60	Invitrogen	60	90	Fluoroquench
197	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	6	1	1	1	4	1	1	17-Jul	17-Jul	No	85	Cedarlane	45	90	Fluoroquench
206	1	1	1	1	1	1	1	1	17-Jul	17-Jul	Yes	80	Cedarlane	30	45	Fluoroquench
209									16-Jul	16-Jul	Yes	90		30	60	Fluoroquench
210	0	0	0	0	0	0	0	0	17-Jul	17-Jul	Yes	80	Biorad	30	60	
223	NT	NT	NT	NT					18-Jul	21-Jul	Yes	30	Biorad	45	60	EB/AO
227									16-Jul	16-Jul	Yes	98	Immucor	30	60	Fluoroquench
238	1	4	1	1	1	4	1	1	16-Jul	17-Jul	Yes	85	Invitrogen	45	90	Fluoroquench
243	2	6	NT	2					16-Jul	17-Jul	Yes	80	Biorad	30	60	Fluoroquench
245	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	100	BAG	30	45	EB/AO
252	1	1	1-2	1	1	2	1-2	1	17-Jul	17-Jul	Yes	30	One Lambda	30	60	
259									17-Jul	17-Jul	Yes	80	Biorad	30	60	AO/PI
260									17-Jul	17-Jul	Yes	85	Biorad	30	60	EB/AO
262		6				6			17-Jul	17-Jul	Yes	90	Invitrogen	60	90	Eosin
268	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	40	Gentrak	30	60	EB/AO
284	1	2	1	1	1	2	1	1	16-Jul	16-Jul	Yes	99	Cedarlane	40	60	EB/AO
293									17-Jul	17-Jul	Yes	80	Invitrogen	60	120	Eosin
294	0	0	0	0					16-Jul	17-Jul	Yes	100	Pel-Freeze	30	30	Fluoroquench
297	1	2	1	1	1	2	1	1	17-Jul	17-Jul	Yes	>90	Cedarlane	30	60	Fluoroquench